Target Name: MIR4750
NCBI ID: G100616314
Review Report on MIR4750 Target / Biomarker Content of Review Report on MIR4750 Target / Biomarker
MIR4750
Other Name(s): hsa-miR-4750-5p | mir-4750 | microRNA 4750 | MicroRNA 4750 | hsa-mir-4750 | hsa-miR-4750-3p

MIR4750: A Potential Drug Target and Biomarker

Mir4750 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its primary function is to regulate the blood flow to the body's tissues, which is critical for maintaining healthy blood pressure and oxygen supply. MIR4750 has also been shown to play a key role in the development and progression of various diseases, including cancer.

Recent studies have suggested that MIR4750 may be a potential drug target and biomarker for a variety of diseases, including cancer. One of the main reasons for these studies is the fact that MIR4750 has been shown to be highly expressed in many types of cancer, including breast, lung, and ovarian cancer. This suggests that targeting MIR4750 may be a effective way to treat these cancers.

In addition to its potential as a cancer drug target, MIR4750 has also been shown to be a potential biomarker for several types of cancer. For example, studies have shown that MIR4750 levels are significantly elevated in the blood samples of patients with breast cancer, and that these levels can be used as a biomarker for this type of cancer. Similar studies have been done for lung and ovarian cancer, and the results have been consistent.

Another potential benefit of MIR4750 as a drug target is its ability to cross the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the rest of the body, and it is designed to protect the brain from harmful substances. However, this barrier can also prevent the delivery of drugs to the brain, which can be a challenge in treating certain types of cancer. By crossing the blood-brain barrier, MIR4750 may be able to deliver drugs directly to the brain and may be more effective in treating certain types of cancer.

MIR4750 has also been shown to play a key role in the regulation of blood pressure and heart rate, which is critical for maintaining healthy blood flow to the body's tissues. Studies have shown that MIR4750 has a negative impact on blood pressure and heart rate in both humans and animals, and that this may be related to its function as a blood flow regulator. This suggests that targeting MIR4750 may be a potential way to treat hypertension and other conditions that are related to poor blood flow.

In addition to its potential as a drug target and biomarker, MIR4750 has also been shown to play a key role in the development and progression of various diseases. For example, studies have shown that MIR4750 is expressed in the brains of patients with Alzheimer's disease, and that this may be related to the progressive nature of this disease. Similarly, MIR4750 has also been shown to be expressed in the brains of patients with Parkinson's disease, and the results of these studies suggest that targeting MIR4750 may be a potential way to treat these conditions.

Overall, MIR4750 is a protein that has been shown to play a key role in the regulation of blood flow, and has been shown to be highly expressed in a variety of diseases, including cancer. The potential drug target and biomarker properties of MIR4750 make it an attractive target for further research and may lead to new treatments for a variety of diseases.

Protein Name: MicroRNA 4750

The "MIR4750 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4750 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4751 | MIR4752 | MIR4753 | MIR4754 | MIR4755 | MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767 | MIR4768 | MIR4769 | MIR4770 | MIR4771-1 | MIR4771-2 | MIR4772 | MIR4773-1 | MIR4773-2 | MIR4774 | MIR4775 | MIR4776-1 | MIR4776-2 | MIR4777 | MIR4778 | MIR4779 | MIR4780 | MIR4781 | MIR4782 | MIR4783 | MIR4784 | MIR4785 | MIR4786 | MIR4787 | MIR4789 | MIR4790 | MIR4791 | MIR4793 | MIR4794 | MIR4795 | MIR4796 | MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490 | MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004 | MIR5006 | MIR5007 | MIR5008 | MIR5009 | MIR500A | MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088